Xience, diagnostics help fuel Abbott's Q1 sales growth
April 21, 2010 by MassDevice staff
Strong sales of Xience stents overseas and diagnostics tools back home contribute to Abbott's $7.7 billion in first-quarter revenues; net profit tops $1 billion, down 30 percent from 2009 levels.
Paced by strong international growth, coronary stent sales for Abbott (NYSE:ABT) rose 13 percent during the first three months of 2010, to $455 million.
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- Is Valeant About To Make A Bold Bid For Bausch & Lomb?
- When regulators are ignored
- FDA Issues Draft Guidance to Help Companies Distinguish Between a Voluntary Medical Device Recall and a Product Enhancement
- Patient and family engagement in ICUs
- A day in the life: A pediatric neurosurgeon's vision
- Medical Device Tax: Are Conservatives' goals hampering repeal efforts?
- Personal health record use by adolescents
- Can Johnson & Johnson fire on all cylinders again?
- U.S. FDA to require proof of IEC 60601-1 3rd Edition in summer 2013
- A cure for coffee breath?
Navigation
NEWS
Uroplasty touts positive 3-year outcomes for neurostimulation in treatment of overactive bladder
Covidien’s 3-year study results showing positive outcomes for its Urgent PC Neuromodulation system in...
FDA clears 21-inch medical monitors from NEC Display Solutions
NEC Display Solutions wins 510(k) clearance for its 21-inch medical monitor systems.
Johnson and Johnson executive splits for the corner office at Itamar Medical | Personnel Moves
J&J's former head of global cardiology makes the jump to CEO at Itamar Medical
Sunshine Heart seeks $25.5M in equity funding round | Wall Street Beat
Sunshine Heart raises $1.5 million of a hoped-for $25.5 million equity funding round.
J&J sues Shasta Technologies for logo infringement
J&J subsidiary Lifescan asks the courts to ban Shasta from using its logo, saying problems with...
